keyword
MENU ▼
Read by QxMD icon Read
search

Neuro oncology

keyword
https://www.readbyqxmd.com/read/28531344/citation-classics-in-neuro-oncology-assessment-of-historical-trends-and-scientific-progress
#1
Laureen D Hachem, Alireza Mansouri, Kyle Juraschka, Shervin Taslimi, Farhad Pirouzmand, Gelareh Zadeh
Background.: Citation classics represent the highest cited works in a field and are often regarded as the most influential literature. Analyzing thematic trends in citation classics across eras enables recognition of important historical advances within a field. We present the first analysis of the citation classics in neuro-oncology. Methods.: The Web of Science database was searched using terms relevant to "neuro-oncology." Articles with >400 citations were identified and the top 100 cited articles were evaluated...
May 20, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28531331/diagnostic-challenges-in-meningioma
#2
Martha Nowosielski, Nobert Galldiks, Sarah Iglseder, Philipp Kickingereder, Andreas von Deimling, Martin Bendszus, Wolfgang Wick, Felix Sahm
Advances in molecular profiling and the application of advanced imaging techniques are currently refreshing diagnostic considerations in meningioma patients. Not only technical refinements but also sophisticated histopathological and molecular studies have the potential to overcome some of the challenges during meningioma management. Exact tumor delineation, assessment of tumor growth and pathophysiological parameters were recently addressed by "advanced" magnetic resonance imaging and positron emission tomography...
May 20, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28527007/factors-associated-with-supportive-care-needs-in-glioma-patients-in-the-neuro-oncological-outpatient-setting
#3
Mirjam Renovanz, Marlene Hechtner, Mareile Janko, Karoline Kohlmann, Jan Coburger, Minou Nadji-Ohl, Jochem König, Florian Ringel, Susanne Singer, Anne-Katrin Hickmann
Objective of this study aimed at assessing glioma patients' supportive care needs in a neurosurgical outpatient setting and identifying factors that are associated with needs for support. In three neuro-oncological outpatient departments, glioma patients were assessed for their psychosocial needs using the Supportive Care Needs Survey short-form (SCNS-SF34-G). Associations between clinical, sociodemographic, treatment related factors as well as distress (measured with the distress thermometer) and supportive care needs were explored using multivariable general linear models...
May 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28522182/hodotopy-neuroplasticity-and-diffuse-gliomas
#4
H Duffau
BACKGROUND AND PURPOSE: The historical approach in neurooncology is used to mainly investigate the tumor, with very few considerations regarding the brain itself. Nonetheless, to select the best personalized therapeutic management for each patient with a diffuse glioma, i.e. to optimize the "onco-functional balance", the brain reaction induced by glioma growth and migration should be studied. Indeed, due to strong interactions between the glioma and the brain, cerebral adaptive phenomena often occur in order to maintain neurological and cognitive functions, as well as to compensate glioma spreading...
May 15, 2017: Neuro-Chirurgie
https://www.readbyqxmd.com/read/28516376/an-update-on-the-approach-to-the-imaging-of-brain-tumors
#5
REVIEW
Katherine M Mullen, Raymond Y Huang
PURPOSE OF REVIEW: Neuroimaging plays a critical role in diagnosis of brain tumors and in assessment of response to therapy. However, challenges remain, including accurately and reproducibly assessing response to therapy, defining endpoints for neuro-oncology trials, providing prognostic information, and differentiating progressive disease from post-therapeutic changes particularly in the setting of antiangiogenic and other novel therapies. RECENT FINDINGS: Recent advances in the imaging of brain tumors include application of advanced MRI imaging techniques to assess tumor response to therapy and analysis of imaging features correlating to molecular markers, grade, and prognosis...
July 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28512049/space-occupying-tumor-bed-cysts-as-a-complication-of-modern-treatment-for-high-grade-glioma
#6
Thomas Beez, Sven Burgula, Marcel Kamp, Marion Rapp, Hans-Jakob Steiger, Michael Sabel
INTRODUCTION: Management of high grade glioma (HGG) was changed by recent landmark trials and is nowadays more proactive. However, aggressive treatment leads to hospitalization due to side effects. Space-occupying tumor bed cysts have been described, but not systematically assessed. We sought to analyze this complication in a contemporary HGG cohort. METHODS: A retrospective review of HGG patients treated between 2007 and 2013 was performed, patients with space-occupying tumor bed cysts were identified and their hospital notes reviewed for relevant variables...
May 13, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28512039/fluorescein-guided-surgery-for-high-grade-glioma-resection-an-intraoperative-contrast-enhancer
#7
Giuseppe Catapano, Francesco Giovanni Sgulò, Vincenzo Seneca, Giovanni Lepore, Laura Columbano, Giuseppe di Nuzzo
BACKGROUND: Fluorescein sodium salt is widely used in medicine as fluorescein isothiocyanate and commonly named fluorescein (FL). This fluorophore has been used as a fluorescent tracer for many applications, especially in ophthalmic surgery. The initial use in neuro-oncologic field occurred in 1948 in order to control tumor resection margins. After a transient disuse, it has recently had a second spring with the development of dedicated filters for operating microscope, although it is still under evaluation in clinical use...
May 13, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28500559/nivolumab-for-patients-with-recurrent-glioblastoma-progressing-on-bevacizumab-a-retrospective-case-series
#8
Marc C Chamberlain, Bryan T Kim
A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 52-72 years (median 62), with recurrent GBM were treated. All patients had previously been treated with surgery, concurrent radiotherapy and temozolomide, and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was administered to all patients at first recurrence...
May 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28485386/monitoring-rate-and-predictability-of-intraoperative-monitoring-in-patients-with-intradural-extramedullary-and-epidural-metastatic-spinal-tumors
#9
H Kang, H S Gwak, S H Shin, M K Woo, I H Jeong, H Yoo, J W Kwon, S H Lee
STUDY DESIGN: Single-center retrospective study. OBJECTIVES: To evaluate the monitoring rate, sensitivity and specificity of intraoperative monitoring (IOM) during removal of intradural extramedullary (IDEM) or epidural metastatic spinal tumors. Also, to assess the efficacy of monitoring somatosensory-evoked potentials (SSEP) when motor-evoked potentials (MEP) are not measurable. SETTING: The Neuro-Oncology Clinic, National Cancer Center, Korea...
May 9, 2017: Spinal Cord
https://www.readbyqxmd.com/read/28483413/european-association-for-neuro-oncology-eano-guideline-on-the-diagnosis-and-treatment-of-adult-astrocytic-and-oligodendroglial-gliomas
#10
REVIEW
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot, Martin Bendszus, Jaap C Reijneveld, Frederick Dhermain, Pim French, Christine Marosi, Colin Watts, Ingela Oberg, Geoffrey Pilkington, Brigitta G Baumert, Martin J B Taphoorn, Monika Hegi, Manfred Westphal, Guido Reifenberger, Riccardo Soffietti, Wolfgang Wick
The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also integrated the results from contemporary clinical trials that have changed clinical practice...
May 5, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28472964/reliability-and-validity-of-the-sf-36-health-survey-questionnaire-in-patients-with-brain-tumors-a-cross-sectional-study
#11
Adomas Bunevicius
BACKGROUND: Deterioration of health related quality of life (HRQoL) is common in brain tumor patients. This study evaluated validity and reliability of the Medical Outcomes Study 36-Item Short Form (SF-36) in patients with brain tumors. METHODS: Two hundred and seventy-seven patients admitted for brain tumor surgery were evaluated for HRQoL (SF-36 questionnaire); depressive symptoms (Beck Depression Inventory-II or BDI-II); and functional status (Barthel index or BI)...
May 4, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28466127/incidence-of-tumour-progression-and-pseudoprogression-in-high-grade-gliomas-a%C3%A2-systematic-review-and-meta-analysis
#12
Abdul W Abbasi, Henriette E Westerlaan, Gea A Holtman, Kamal M Aden, Peter Jan van Laar, Anouk van der Hoorn
BACKGROUND: High-grade gliomas are the most common primary brain tumours. Pseudoprogression describes the false appearance of radiation-induced progression on MRI. A distinction should be made from true tumour progression to correctly plan treatment. However, there is wide variation of reported pseudoprogression. We thus aimed to establish the incidence of pseudoprogression and tumour progression in high-grade glioma patients with a systematic review and meta-analysis. METHODS: We searched PubMed, Embase and Web of Science on the incidence of pseudoprogression and tumour progression in adult high-grade glioma patients from 2005, the latest on 8 October 2014...
May 2, 2017: Clinical Neuroradiology
https://www.readbyqxmd.com/read/28455788/diagnosis-and-treatment-patterns-for-patients-with-leptomeningeal-metastasis-from-solid-tumors-across-europe
#13
Emilie Le Rhun, Roberta Rudà, Patrick Devos, Khê Hoang-Xuan, Dieta Brandsma, Pedro Pérez Segura, Riccardo Soffietti, Michael Weller
Leptomeningeal metastases are a late manifestation of systemic cancer which affects up to 10% of patients with solid tumors. Prognosis is poor, and overall survival at 1 year is only approximately 10%. Management depends mainly on general and neurological condition, primary tumor, and patterns of metastasis, notably absence or presence of concurrent systemic or solid brain metastases. Here we set out to characterize current practice patterns of diagnosis and treatment of patients with leptomeningeal metastasis in Europe...
April 28, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28453751/the-neurologic-assessment-in-neuro-oncology-nano-scale-a-tool-to-assess-neurologic-function-for-integration-into-the-response-assessment-in-neuro-oncology-rano-criteria
#14
Lakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, David M Peereboom, Evanthia Galanis, Nancy U Lin, Riccardo Soffietti, David R Macdonald, Marc Chamberlain, James Perry, Kurt Jaeckle, Minesh Mehta, Roger Stupp, Alona Muzikansky, Elena Pentsova, Timothy Cloughesy, Fabio M Iwamoto, Joerg-Christian Tonn, Michael A Vogelbaum, Patrick Y Wen, Martin J van den Bent, David A Reardon
Background.: The Macdonald criteria and the Response Assessment in Neuro-Oncology (RANO) criteria define radiologic parameters to classify therapeutic outcome among patients with malignant glioma and specify that clinical status must be incorporated and prioritized for overall assessment. But neither provides specific parameters to do so. We hypothesized that a standardized metric to measure neurologic function will permit more effective overall response assessment in neuro-oncology. Methods...
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28453743/targeted-next-generation-sequencing-of-pediatric-neuro-oncology-patients-improves-diagnosis-identifies-pathogenic-germline-mutations-and-directs-targeted-therapy
#15
Cassie N Kline, Nancy M Joseph, James P Grenert, Jessica van Ziffle, Eric Talevich, Courtney Onodera, Mariam Aboian, Soonmee Cha, David R Raleigh, Steve Braunstein, Joseph Torkildson, David Samuel, Michelle Bloomer, Alejandra G de Alba Campomanes, Anuradha Banerjee, Nicholas Butowski, Corey Raffel, Tarik Tihan, Andrew W Bollen, Joanna J Phillips, W Michael Korn, Iwei Yeh, Boris C Bastian, Nalin Gupta, Sabine Mueller, Arie Perry, Theodore Nicolaides, David A Solomon
Background.: Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neuro-oncology patients. Methods.: We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes. Results.: Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor...
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28449033/response-assessment-in-medulloblastoma-and-leptomeningeal-seeding-tumors-recommendations-from-the-response-assessment-in-pediatric-neuro-oncology-committee
#16
Katherine E Warren, Gilbert Vezina, Tina Y Poussaint, Monika Warmuth-Metz, Marc C Chamberlain, Roger J Packer, Alba A Brandes, Moshe Reiss, Stewart Goldman, Michael J Fisher, Ian F Pollack, Michael D Prados, Patrick Y Wen, Susan M Chang, Christelle Dufour, David Zurakowski, Rolf D Kortmann, Mark W Kieran
Lack of standard response criteria in clinical trials for medulloblastoma and other seeding tumors complicates assessment of therapeutic efficacy and comparisons across studies. An international working group was established to develop consensus recommendations for response assessment. The aim is that these recommendations be prospectively evaluated in clinical trials, with the goal of achieving more reliable risk stratification and uniformity across clinical trials. Current practices and literature review were performed to identify major confounding issues and justify subsequently developed recommendations; in areas lacking scientific investigations, recommendations were based on experience of committee members and consensus was reached after discussion...
April 25, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28441372/assessing-response-of-high-grade-gliomas-to-immune-checkpoint-inhibitors
#17
Solmaz Sahebjam, Dexter G Stallworth, Sepideh Mokhtari, Nam D Tran, John A Arrington
BACKGROUND: Immunotherapeutic agents, especially checkpoint inhibitors, have emerged as the mainstay of therapy for several solid and hematological malignancies. These therapies are under investigation for the treatment of high-grade gliomas and brain metastases. METHODS: This article reviews the unique challenges encountered when evaluating changes on magnetic resonance imaging (MRI) of glioblastomas seen in response to immunotherapy and checkpoint inhibitors and how to effectively incorporate MRI findings into the response assessment of high-grade gliomas to these emerging therapies...
April 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28435297/the-role-of-kpn%C3%AE-1-in-neuro-oncology
#18
EDITORIAL
Megan Lilley, Faris Farassati
No abstract text is available yet for this article.
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28421461/the-role-of-tumor-board-conferences-in-neuro-oncology-a-nationwide-provider-survey
#19
REVIEW
James Snyder, Lonni Schultz, Tobias Walbert
The tumor board or multidisciplinary cancer meeting (MCM) is the foundation of high value multidisciplinary oncology care, coordinating teams of specialists. Little is known on how these meetings are implemented in Neuro-oncology. Benefits of MCMs include coordination, direction for complicated cases, education, and a forum for communication, emerging technology, and clinical trials. This study identifies participation and utilization of neuro-oncology MCMs. A cross-sectional descriptive survey was dispersed through an internet questionnaire...
April 18, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28417344/biotherapy-in-inflammatory-diseases-of-the-cns-current-knowledge-and-applications
#20
REVIEW
Nicolas Collongues, Laure Michel, Jérôme de Seze
Biotherapy represents an innovative therapeutic approach that includes immunotherapy (vaccines, apheresis, and antibodies); gene therapy; and stem cell transplants. Their development helps to cross the bridge from bench to bedside and brings new hope of a cure for severe diseases in different fields of medicine. In neurology, a growing range of applications is being developed for these medications. Valuable results are now available in the field of autoimmunity, neuro-oncology, paraneoplastic manifestations, and neurodegenerative disorders...
May 2017: Current Treatment Options in Neurology
keyword
keyword
14974
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"